Spirola

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spirola

What is Spirola? Definitive Identity and Purpose

Property Description
Active ingredient Spironolactone
Form Oral Tablet
Pharmacological class Potassium-sparing Diuretic, Aldosterone Receptor Antagonist (ARA)
General purpose Fluid balance regulation, Blood pressure control
Origin Synthetic steroidal compound

The drug Spirola is a prescription-only medication (Rx) containing the active ingredient Spironolactone. This substance is a synthetic steroidal compound. Spirola's classification is rooted in its pharmacological action as both a Potassium-sparing diuretic and an Aldosterone Receptor Antagonist (ARA). Its overall purpose is to contribute to effective fluid balance regulation and act as an antihypertensive agent.


What Type of Medicine is Spirola and What Does It Contain?

The medicine is primarily classified by its mechanism: it is an ARA that functions by selectively blocking the action of the hormone aldosterone at receptor sites in the kidneys, a mechanism used in regulating salt and water balance. Spirola is a single-agent product, with its primary preparation being an oral tablet for systemic administration.


The Unique "Potassium-Sparing" Principle

The characteristic Potassium-sparing action is a key differentiator for this medicine. While it successfully promotes the loss of unneeded sodium and water from the body via urination, its specific ARA mechanism helps the kidneys retain potassium. This distinct action helps maintain stable and healthy potassium levels, mitigating the risk of the electrolyte imbalances commonly associated with other non-sparing diuretic therapies. Spironolactone is utilized as a diuretic for the management of edema (fluid retention).

What side effects are possible with Spirola?

Possible side effects and safety information

The official safety documents for Spirola (Spironolactone) detail adverse reactions classified by frequency and affected body system. The primary safety concern documented is Hyperkalemia (elevated potassium levels), which is listed as a very common adverse reaction, particularly in patients with severe renal impairment or severe heart failure. Hyperkalemia is also cited as a potential severe or fatal adverse reaction.


Key Adverse Reactions and Organ Systems

Adverse effects are grouped by System-Organ Class (SOC) categories in regulatory labeling:

  • Reproductive System and Breast Disorders: These are commonly observed effects, including Gynecomastia (male breast enlargement), breast pain, and menstrual irregularities.
  • Nervous System Disorders: Common reactions include headache, dizziness, and drowsiness (lethargy).
  • Gastrointestinal Disorders: Effects such as nausea, vomiting, and diarrhea are commonly reported.
  • Skin and Subcutaneous Tissue Disorders: Includes common effects like rash, as well as rare but severe reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms).

Safety Considerations and Restrictions

Official labels note several important safety patterns. Gynecomastia is often described as dose-related and associated with long-term therapy. The risk of Hyperkalemia is higher following treatment initiation or dose increases. Spirola is contraindicated in patients with pre-existing Hyperkalemia, Addison’s disease, anuria, or significant acute renal insufficiency. Special caution and closer monitoring of electrolytes and kidney function are required for older adults and patients with pre-existing hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section describes only the overdose manifestations and emergency actions documented in government regulatory sources, such as the FDA Prescribing Information.

Overdose scope

Feature Regulatory Documentation Statement
Documented overdose presentations Drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea.
Physiological systems affected Central Nervous System (CNS), Gastrointestinal (GI), Dermatologic, and Electrolyte/Metabolic.
Population-specific overdose notes Hyperkalemia (high potassium) risk is increased in patients with impaired renal function. Hepatic coma may rarely occur in patients with severe liver disease.
Emergency-response statements Evacuate the stomach by lavage or induce vomiting are documented treatment procedures.
When immediate medical help is required Seek medical attention immediately for severe symptoms, including collapse, seizure, unconsciousness, or signs of severe electrolyte imbalance like an irregular heartbeat.

Overdose classifications (high-level)

Classification Regulatory Documentation Statement
Severity classification Hyperkalemia is cited as a serious outcome that may be fatal.
Overdose-context constraints No specific antidote is known; treatment is supportive to maintain hydration, electrolyte balance, and vital functions.

Resulting overdose structure

  • The primary life-threatening risk is the development of severe Hyperkalemia, which requires prompt medical management.
  • Treatment is defined as symptomatic and supportive, with no specific antidote available according to official labeling.
  • Urgent medical attention is mandated for the occurrence of severe symptoms, particularly those affecting the CNS or cardiovascular system.

Connection to the overall overdose profile

Regulatory documents define the overdose profile around the consequences of excessive mineralocorticoid antagonism, requiring immediate access to medical care for active management of electrolyte balance. The documented lack of a specific antidote establishes the mandated treatment approach as procedural (stomach evacuation) and supportive.

Therapeutic Uses of Spirola

Managing Fluid Retention and Swelling (Edema)

Spirola is generally applied across domains where additional symptomatic support is needed to address groups of symptoms that cause noticeable swelling, puffiness, or bloating (edema). It is commonly used across conditions presenting with fluid retention and is relevant for managing symptoms that interfere with daily comfort. By providing supportive relief, Spirola assists with maintaining functional stability when symptoms are more noticeable.


Supporting High Blood Pressure and Systemic Balance

This medication is commonly used across conditions presenting with symptoms related to systemic imbalance, such as persistent high blood pressure (hypertension). It supports general well-being during symptomatic phases and contributes to a more stable cardiovascular state. The medication may be part of symptomatic management to help patients cope more steadily with challenging symptoms.


Addressing Hormonal Skin and Hair Symptoms

Applied in situations involving certain distressing symptoms in women related to hormonal imbalances, this treatment is relevant for easing symptoms like specific patterns of acne or unwanted, excessive hair growth. It assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic phases.


Quick Fact: Relief for Fluid Imbalance The treatment is commonly used to help manage symptoms of fluid retention that interfere with daily comfort, which may include noticeable swelling.

Eligibility and Restrictions for Use

Who Can and Cannot Use Spirola? Official Eligibility Rules

The eligibility to use Spirola (Spironolactone) is strictly defined by regulatory authorities and depends primarily on a patient’s existing conditions, age, and physiological state. The constraints focus on mitigating the risk of dangerously high potassium levels and potential kidney compromise.

Eligibility Status Population Restriction
Contraindicated Patients with Hyperkalemia (high blood potassium), Addison’s disease, Anuria (inability to pass urine), acute renal insufficiency, or those concurrently taking Eplerenone must not use this medicine.
Conditional Use Use in severe Heart Failure is only allowed if serum potassium and creatinine levels meet specific, low regulatory thresholds. Older adults require cautious use due to higher risk of kidney impairment.
Age and Function Spirola is generally approved for Adults. Use in children requires specialist oversight and is contraindicated in pediatric patients with moderate-to-severe kidney disease.
Pregnancy/Lactation Use during pregnancy is generally avoided due to potential risk. The medicine is not recommended for use while breastfeeding.

These eligibility rules reflect the official, non-advisory constraints documented by regulatory bodies to prevent use in populations most susceptible to the drug's known physiological risks.

What should I know about interactions with other medicines?

The official regulatory profile for Spirola documents several significant interaction patterns based on its pharmacological activity and metabolic profile.

Formal Restrictions and Contraindicated Combinations

Co-administration is contraindicated with certain agents due to the documented risk of severe hyperkalemia (high potassium levels). These agents include Eplerenone, other Potassium-Sparing Diuretics (e.g., Triamterene), and Potassium Supplements or salt substitutes. The use of Spirola is also not recommended in combination with Abiraterone, as Spirola binds to the androgen receptor and may compromise the therapeutic efficacy of Abiraterone.

Clinically Significant Pharmacodynamic and Exposure Interactions

Interactions that increase the risk of hyperkalemia require careful monitoring and involve co-administration with ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Heparin, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Furthermore, Spirola is documented to increase serum Digoxin concentration and reduce the renal clearance of Lithium, raising the risk of toxicity for both agents. The medicine is also shown to enhance the metabolism of Antipyrine and reduce Mitotane plasma levels.

Population and Administration Constraints

A population-specific constraint notes that the medicine is contraindicated in pediatric patients with moderate to severe renal impairment. A pharmacokinetic constraint exists with food, as taking Spirola with food increases its bioavailability by approximately 95%.


Mechanism of Action

Spironolactone's mechanism involves competitive antagonism at key steroid hormone receptors, resulting in specific physiological effects by interrupting defined signaling cascades.

Kidney Pathway Modulation and Fluid Homeostasis

The drug's active metabolites block the Mineralocorticoid Receptor (MR) in the kidney, preventing aldosterone from stimulating sodium and water reabsorption while simultaneously inhibiting potassium secretion. This action alters the exchange dynamics of sodium and potassium ions and leads to the net excretion of sodium and fluid, which subsequently influences overall systemic fluid volume.

Extra-Renal Effects on Vascular and Cardiac Tissues

Spiro also engages the Mineralocorticoid Receptor (MR) in non-epithelial tissues, such as the heart and blood vessels. By blocking aldosterone's activity here, the drug modulates pathways associated with inflammation and tissue remodeling. This mechanistic domain results in the attenuation of structural remodeling and fibrosis in cardiovascular tissues.

Interference with Androgen Signaling Pathways

Due to its structural nature, the drug exhibits cross-reactivity by acting as a competitive antagonist at the Androgen Receptor (AR) in specific peripheral tissues. This mechanistic domain interrupts the ability of natural androgens to trigger their cellular effects, resulting in a diminished biological response to these sex hormones.

Dosage and Administration Information

Official Administration Guidelines for Spirola

Spirola (spironolactone) is administered orally and is available in both tablet and oral suspension forms. Dosage is highly individualized and must be adjusted based on the specific condition being treated, the patient's response, and tolerance.

Dosage and Timing

The daily dose may be given as a single dose or in divided doses. It is important to take Spirola at around the same time every day. While the oral tablet may be taken with a meal to minimize potential side effects, the oral suspension must be taken consistently either with food or without food each time it is administered.

Condition (Adult) Initial Dosing Range (Typical)
Essential Hypertension 50 mg/day to 100 mg/day
Severe Heart Failure (NYHA Class III-IV) 25 mg once daily
Edema (e.g., Cirrhosis, Nephrotic Syndrome) 100 mg/day (initial dose for 5 days)

For pediatric patients, the initial dosage is typically 1 mg/kg body weight daily to 3.3 mg/kg body weight daily in divided doses.

Procedural and Safety Rules

  • Preparation: If using the oral suspension, shake the bottle well before each use. Spirola tablets and the oral suspension are not bioequivalent and cannot be substituted for one another without medical dose reassessment.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not take a double dose to compensate.
  • Monitoring: Periodic laboratory testing, including monitoring of serum potassium and creatinine, is required, especially during initiation or dose changes for severe heart failure, where monitoring is recommended at specific intervals.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spirola


Evidence for Management of Fluid Balance and Heart Failure

Research was evaluated in settings exploring this medicine's use as an add-on to existing primary therapies for chronic conditions where fluid imbalance is a factor. For advanced forms of heart failure with reduced pumping function, studies monitored long-term outcomes, focusing on patient hospitalization events and cardiovascular all-cause mortality in large, multi-center, long-term Randomized Controlled Trials (RCTs). The research contributes to the broader evidence landscape by examining its use as a supportive element within comprehensive treatment plans. Limited data is available from studies examining this medicine as a standalone treatment.

For fluid retention (edema) associated with conditions like hepatic cirrhosis or nephrotic syndrome, the evidence base includes historical data and observational studies. Researchers examined parameters related to fluid balance, including the volume of urine output and the clinical reduction of swelling. Research provides insight into short-term changes in fluid management; however, the standalone contribution of the medicine, separate from other concurrently used diuretics, is often difficult to isolate in some study designs.


Evidence for Use in Resistant High Blood Pressure (Hypertension)

This part details the clinical trials that have evaluated the medicine as an add-on therapy for patients whose high blood pressure remains difficult to manage. The research examined settings where standard three-drug regimens were already in place. The evidence comes from dedicated Randomized Controlled Trials (RCTs). Researchers examined outcomes related to outcomes related to systemic or functional imbalance, primarily the shift in Systolic and Diastolic Blood Pressure (BP), objectively assessed using 24-hour ambulatory BP monitoring (ABPM). Data show patterns related to BP readings when the medicine was incorporated into multi-drug regimens. Long-term effects are not fully established regarding the sustained control of BP and the potential prevention of major cardiovascular events over many years, as follow-up durations were often limited to short or medium terms.


Evidence for Hormonal Skin Conditions

Research exploring short-term symptom changes in conditions presenting with cycles of stability and flare-ups, such as persistent acne and excessive hair growth (hirsutism) in women, primarily includes smaller-scale placebo-controlled trials and retrospective observational studies. Studies monitored outcomes related to outcomes related to physical discomfort, specifically using clinical scoring for acne lesion counts and severity. A key limitation is that the evidence base is supported by a paucity of large-scale, long-term, double-blind RCTs specifically designed for these dermatological outcomes, meaning certainty remains low.

Frequently Asked Questions (FAQ)

Common questions about Spirola (FAQ)

Q: Can Spirola be taken if I am already taking over-the-counter pain relievers?

Official product information indicates that Spirola can interact with certain types of pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This combination may increase the risk of specific side effects or lessen the drug's intended action. Official documents include a caution that any co-administration should be confirmed as appropriate.


Q: Does Spirola interact with common vitamins or supplements?

Regulatory documents advise against using potassium supplements or salt substitutes that contain potassium. This is because Spirola is designed to help the body retain potassium, and combining it with external sources may contribute to the risk of developing elevated potassium levels (hyperkalemia).


Q: Is Spirola considered safe to take long-term, according to research?

For conditions like severe heart failure, official research supports the long-term use of Spirola to improve outcomes and reduce hospitalizations. However, regulatory warnings also note that the drug was shown to cause tumors in chronic toxicity studies in rats. For this reason, official labeling includes the recommendation to avoid unnecessary use of the medicine.


Q: Do I need to take Spirola with food, or does it matter?

Official pharmacokinetic data indicates that taking Spirola with food significantly impacts how the drug is absorbed by the body. Taking it with a meal increases the total amount of the medicine available to the body (bioavailability) by approximately 95%.


Q: How soon after stopping Spirola do the drug's effects wear off?

Regulatory pharmacokinetic studies describe how the body processes the medicine. The drug's active substance, called canrenone, has a long half-life of up to 16.5 hours. This means that even after the last tablet is taken, the active compound can persist in the body for an extended duration.


Q: Are the side effects of Spirola usually temporary?

The regulatory documentation does not typically specify the duration for all common side effects. However, one commonly observed effect in males—the enlargement of breast tissue (Gynecomastia)—is described as being related to the dose and associated with long-term therapy. This suggests that certain effects may not be temporary while the drug is in use.


Q: How does Spirola affect hormones in the body?

Spirola is documented to have several actions on hormones in the body. Its primary function is to block the mineralocorticoid receptor, but it also engages in anti-androgenic and progestogenic activities. This means the drug can interrupt the effects of both the body's natural male sex hormones (androgens) and progesterone.


Q: How long does it usually take to feel the effects of Spirola?

Regulatory pharmacokinetic data can provide an indication of how quickly the drug enters the bloodstream. The active ingredient and its key metabolite generally reach their highest concentrations in the blood between 2.6 hours and 4.3 hours after a dose is administered.


Q: Is it normal to feel a little tired when first starting Spirola?

Official labeling lists drowsiness (lethargy) and dizziness as common adverse reactions. These types of central nervous system effects are noted as most likely to occur at the beginning of treatment when the body is adjusting to the medicine.


Q: Why is Spirola sometimes used for purposes other than its primary indication?

Official documents explain that the drug’s mechanism involves blocking the effects of androgens (male sex hormones) in the body by antagonizing the Androgen Receptor. This specific physiological effect provides the rationale for its use in certain conditions related to hormone imbalances, beyond its primary use for fluid balance.


Q: Can Spirola affect my ability to drive or operate machinery?

Because official safety information lists adverse reactions such as dizziness and drowsiness, caution is advised. Official safety information includes a caution about driving or operating heavy machinery until a person knows how the medicine affects them.


Q: Has Spirola been studied in children or teenagers?

Official prescribing information contains a dedicated section on Pediatric Use. This confirms that the drug is approved and can be administered to children under the supervision of a healthcare professional.


Q: Does Spirola affect sleep patterns?

Regulatory safety documentation lists drowsiness as a common adverse reaction. Additionally, official information on overdosage includes the symptom of difficulty with sleeping (insomnia) and disorientation, indicating a potential connection to sleep patterns.


Q: Is Spirola known to cause any changes in mood?

Yes, official safety documentation lists both mental confusion and mood or other mental changes as possible adverse reactions. These effects are often associated with central nervous system impact and are also cited as symptoms in cases of overdosage.


Q: What should I do if I feel dizzy after starting Spirola?

Official patient safety information states that if a person experiences dizziness, they are directed to lie down to avoid fainting. Before standing, the guidance suggests sitting for a few moments to help prevent the dizziness from returning.


Q: Can Spirola be used if a person has high blood pressure?

Official regulatory indications confirm that Spirola is an approved treatment option for managing Hypertension (high blood pressure). It is often utilized as an add-on therapy for patients whose blood pressure is not adequately managed by other medications.


Q: Is Spirola safe for people who have liver disease?

Official documents indicate that the medicine is approved for treating fluid retention associated with a condition like hepatic cirrhosis. However, patients with any pre-existing liver impairment require careful monitoring and special caution. It is generally contraindicated in cases of severe liver disease due to an increased risk of hepatic coma.


Q: Do the official prescribing documents mention Spirola's effect on fertility?

Yes, the official prescribing information includes a specific section that addresses Impairment of Fertility. This section summarizes findings from nonclinical studies, which observed effects on male fertility in animal models.


Q: Are there any known long-term complications associated with Spirola use?

The official WARNING section in regulatory documents highlights findings from animal studies. In chronic toxicity studies in rats, the drug was shown to be a tumorigen (a substance capable of causing tumors). Based on these findings, official labeling includes the recommendation to avoid unnecessary use of the medicine.


Q: Can I cut or crush Spirola tablets if they are hard to swallow?

Regulatory safety guidance states that the tablet is intended to be swallowed whole and not broken, crushed, or chewed. This is partly due to the classification of the drug as a hazardous substance, meaning its contents require special handling precautions if released from the intact tablet.


Q: Is it true that Spirola can cause skin sensitivity to the sun?

Official patient safety information includes caution regarding sun exposure and the need for protective measures like sunscreen and clothing are noted. This advice is provided because of a noted increased risk of certain types of skin cancer.


Q: Is it true that Spirola is sometimes prescribed for women more often than men?

This medicine's mechanism involves blocking androgen (male sex hormone) receptors, which is useful for treating conditions like hormonal acne and excessive hair growth that predominantly affect women. Furthermore, the risk of feminization prevents its high-dose use in men, supporting the pattern of more frequent prescription for women.

How should Spirola be stored and disposed of?

How to Store and Dispose of Spironolactone

The storage and disposal of Spironolactone (Spirola) tablets are subject to specific requirements outlined in official regulatory labeling to ensure product integrity and safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at controlled room temperature, below 77 F (25 C).
Container Keep in the original container and ensure it is tightly closed.
Environment Protect from excess heat and moisture; do not store in the bathroom.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Regulatory authorities advise using a drug take-back program or pharmacy collection point for unused or expired tablets. Spironolactone is not on the list of medicines recommended for flushing. If a take-back option is unavailable, the tablets may be disposed of in household trash after being mixed with an undesirable substance, and the original packaging must have all personal information removed or concealed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spirola found in:

A-Z Index: